Phenobarbital Linked to Fewer Seizures in Alcohol Withdrawal

One of the oldest questions in medical detox is which medication best protects someone going through alcohol withdrawal.

A new comparative study of 9,424 hospitalized patients adds a substantial data point, linking phenobarbital monotherapy to fewer seizures and less delirium tremens than benzodiazepines.

What the Researchers Compared

The study appeared in Internal and Emergency Medicine on June 8, 2026. Researchers led by Dominique R. Grayeb and colleagues at the University of New Mexico and Allegheny Health Network used the TriNetX Global Collaborative Network, a database of de-identified electronic health records, to identify hospitalized adults treated for alcohol withdrawal syndrome.

One group received phenobarbital with no concurrent benzodiazepine exposure. The other received benzodiazepines. The teams were matched one to one on demographics, comorbid conditions, psychiatric and substance use diagnoses, other medications, and laboratory values, leaving 4,712 patients in each group.

What the Study Found

Phenobarbital was associated with a 30% lower relative risk of seizures and a 48% lower relative risk of delirium tremens. Both differences were statistically significant. Patients on phenobarbital were also less likely to need escalation to additional sedative medication.

On several serious outcomes the two approaches looked similar. There were no statistically significant differences in mechanical ventilation, vasopressor use, aspiration pneumonitis or in-hospital death.

One finding ran the other way. Patients treated with phenobarbital were considerably more likely to be admitted to a critical care setting, with a relative risk of 1.85.

How to Read the Critical Care Finding

That result deserves care rather than alarm. This was a retrospective study of existing records, not a randomized trial, so it shows association rather than cause.

Many hospitals run phenobarbital protocols specifically in intensive care units, which means patients may have landed in critical care because of where the protocol lives and how sick they already were, not because the medication sent them there.

The matching process accounts for a great deal, but it cannot fully separate the drug from the setting or from clinician judgment about severity.

The authors concluded that the findings support phenobarbital as a viable alternative treatment strategy for hospitalized patients with alcohol withdrawal syndrome. They did not conclude that it should replace current first-line care.

Why Medical Detox Matters Here

Every patient in this study was in a hospital. That is the context, and it is the point. Alcohol is one of the few substances where stopping can be more dangerous than continuing.

Withdrawal can escalate from tremor, sweating, anxiety disorder, and a racing pulse to seizures and delirium tremens, a state of severe confusion, agitation, fever, and unstable blood pressure that can be fatal without treatment. Nobody can reliably predict in advance whose withdrawal will turn severe.

This research is about which medication a clinical team reaches for while monitoring someone around the clock. It is not a comparison of home remedies, and nothing in it supports attempting alcohol withdrawal without medical supervision.

Understanding the Two Medications

Benzodiazepines, including lorazepam, diazepam, and chlordiazepoxide, have been the recommended first-line treatment for alcohol withdrawal for decades.

They act on GABA-A receptors, restoring some of the calming signaling that the brain loses when alcohol is suddenly removed. They are usually given on a symptom-triggered basis, often guided by the CIWA-Ar scale.

Phenobarbital is a barbiturate. It also acts on GABA-A receptors but through a different mechanism, and it works on glutamate signaling as well. It has a long half-life, which can smooth out the peaks and troughs of a taper, and that same property is why dosing has to be precise and monitored.

Neither is something a person selects. Both are prescribed and titrated by a clinical team based on withdrawal severity, medical history, liver function, and response.

Finding Medical Detox

Never attempt alcohol or benzodiazepine detox without medical supervision. Both carry a risk of seizures and death when stopped abruptly after sustained heavy use.

When evaluating a detox program, ask what level of care it provides, whether a physician is on site or on call, how withdrawal is assessed and how often, what medications the program uses and whether it has a phenobarbital protocol, and what happens if symptoms escalate overnight.

Detox.com’s directory lists medical detox centers by location, level of care, substances treated, and insurance accepted. Call 800-996-6135(Sponsored) to discuss your options with a treatment specialist.